2024 Recipients of NMD4C and MDC Neuromuscular Fellowship Funding Competition
Together the Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are excited to announce the 2024 recipients of our neuromuscular fellowship funding competition to award postdoctoral fellowships in NMD research and clinical fellowships in neuromuscular medicine and electromyography! NMD4C and MDC are committed to empowering the next generation of early-career researchers and clinicians in building successful careers in neuromuscular disease (NMD) research and clinical practice to improve neuromuscular care, research, treatment, and health outcomes for all Canadians.
The 2024 competition provides salary support for two early-career scientists to conduct postdoctoral studies in laboratories focused on NMD research, and three early-career neurologists to participate in neuromuscular medicine and electromyography training programs. Successful applicants receive $40 000 in funding over a one-year period for postdoctoral fellowships, and $80 000 in funding over a one-year period for clinical fellowships. Since 2022, this competition has provided $1 million in funding to support neuromuscular postdoctoral researchers and clinical fellows in Canada, made possible by generous supporters of MDC, with one clinical fellow each year by the Canadian Society for Clinical Neurophysiologists.
This competition involves an extensive review by leading Canadian neuromuscular researchers and clinicians to ensure the top-ranked candidates are selected for this funding opportunity. From the entire neuromuscular community, congratulations to all 2024 recipients!
Postdoctoral Fellowship Recipients:
Dr. Yassine Ouhaddi Centre de recherche du CHU Sainte-Justine, Montreal, QC
Learn more about the 2024 postdoctoral fellows and their research projects.
Clinical Fellowship Recipients
Dr. Yiu-Chia Chang University of Western Ontario, London, ON
Dr. Mark Krongold University of British Columbia, Vancouver, BC
Dr. Bram De Wel University of Calgary, Calgary, AB
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.